In a report issued yesterday, Canaccord Genuity analyst John Newman assigned a Hold rating on shares of AcelRx Pharmaceuticals (ACRX) with a price target of $8, following ACRX’s Zalviso …
In a research report released yesterday, Roth Capital analyst Ed Arce reiterated a Buy rating on AcelRx Pharmaceuticals Inc. (ACRX) with a price …
